CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Celon Pharma SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Celon Pharma SA
ul. Ogrodowa 2A, Kielpin
Phone: +48 227515933p:+48 227515933 05-092  Poland Ticker: CLNCLN
Business Summary
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board Robert S.Rzeminski
Chairman of the Management Board, Chief Executive Officer MaciejWieczorek
Financial Director, Member of the Management Board BartoszSzalek 7/4/2023 7/4/2023
4 additional Officers and Directors records available in full report.

Business Names
Business Name
CLN
CLNA

General Information
Number of Employees: 513 (As of 9/30/2023)
Outstanding Shares: 51,056,500 (As of 9/30/2023)
Stock Exchange: WAR
Fax Number: +48 227514458


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024